Third, acquisition of BCR-ABL mutation may ironically inhibit its transformation ability in CD34+CD38− cells in the chronic phase CML, somewhat similar to that in KCL-22M cells described above. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.